Celsion Corporation (NASDAQ:CLSN) Jumps 13% On Update of GEN-1 Print
By Marilyn Mullen   
Friday, 20 February 2015 14:52

Shares of thinly-traded nano cap Celsion Corporation (NASDAQ:CLSN) jumped almost 13% to $3.16 on heavy volume in response to its update on its advancement of GEN-1, its DNA-based immunotherapy, for the front-line treatment of advanced platinum-resistant and recurring ovarian cancer.

The FDA has cleared the Phase 1 dose escalation trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer. The trial should commence at five to six U.S. medical centers by mid-year.

The company presents clinical and preclinical data showing the safety, biological activity and clinical benefits of GEN-1 today at the Molecular Medicine TRI-Conference in San Francisco. In an earlier Phase 1 study, GEN-1 demonstrated a disease control rate (DCR) of 31% and median overall survival (OS) of 18 months. In a Phase 2 study, it demonstrated a DCR of 45% and median OS of 10 months. DCR is the proportion of patients who show a response to treatment.

Celsion Corporation is an oncology drug development company. The company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Its lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. Its pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!